iCAD, Inc. (Nasdaq: ICAD) commented on an article published in today's issue of the New England Journal of Medicine entitled ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE